

**NO: 1, 3, or 5 and the corresponding polypeptide SEQ ID NO: 2, 4, or 6 that it encodes, as each sequence presents a structurally and functionally distinct invention not a species.**

**Group II: Claims 10-13, 58-61, drawn to an isolated polypeptide, classified in class 530, subclass 350.**

**Additionally, Applicants must elect a single polypeptide sequence SEQ ID NO: 2, 4, or 6 and the corresponding nucleotide SEQ ID NO: 1, 3, or 5 that encodes it, as each sequence presents a structurally and functionally *distinct* invention not a species.**

**Group III: Claims 14-28, 58-61, drawn to an antibody, classified in Class 530, subclass 387.1.**

**Additionally, Applicants must elect a single polypeptide sequence SEQ ID NO: 2, 4, or 6 that the antibody binds and the corresponding nucleotide SEQ ID NO: 1, 3, or 5 that encodes the polypeptide, as each sequence presents a structurally and functionally *distinct* invention not a species.**

**Group IV: Claims 29-33, drawn to an isolated polynucleotide comprising a sequence that encodes an antibody, classified in class 536, subclass 23.53.**

**Additionally, Applicants must elect a single polypeptide sequence SEQ ID NO: 2, 4, or 6 that the antibody binds and the corresponding nucleotide SEQ ID NO: 1, 3, or 5 that encodes the polypeptide, as each sequence presents a structurally and functionally *distinct* invention not a species.**

**Group V: Claims 34-43, 58-61, drawn to an isolated oligopeptide which binds to a**

polypeptide, classified in Class 530, subclass 300.

**Additionally, Applicants must elect a single polypeptide sequence SEQ ID NO: 2, 4, or 6 which the oligopeptide binds and the corresponding nucleotide SEQ ID NO: 1, 3, or 5 that encodes the polypeptide, as each sequence presents a structurally and functionally *distinct* invention not a species.**

**Group VI: Claims 44-53, 58-61, drawn to a TASK binding organic molecule which binds to a polypeptide, classified in class 530, subclass 300.**

**Additionally, Applicants must elect a single polypeptide sequence SEQ ID NO: 2, 4, or 6 which the TASK binding organic molecule binds the corresponding nucleotide SEQ ID NO: 1, 3, or 5 that encodes the polypeptide, as each sequence presents a structurally and functionally *distinct* invention not a species.**

**Group VII: Claims 54-57, 58-61, drawn to a TASK binding interfering RNA (siRNA) which binds to a nucleic acid, classified in class 536, subclass 24.5;**

**Additionally, Applicants must elect a single nucleic acid sequence SEQ ID NO: 1, 3, or 5 which the TASK binding interfering RNA binds and the corresponding polypeptide SEQ ID NO: 2, 4, or 6 that is encoded by the polynucleotide, as each sequence presents a structurally and functionally *distinct* invention not a species.**

**Group VIII: Claims 62-90 101-102, drawn to a method of inhibiting the growth of a cancer cell that expresses a polypeptide, a method of therapeutically treating a mammal having a tumor that expresses a polypeptide, and a**

method for treating or preventing a cell proliferative disorder associated with increased expression or activity of a polypeptide, classified in class 514, subclass 2.

**Additionally, Applicants must elect single polypeptide sequence SEQ ID NO: 2, 4, or 6 and the corresponding nucleotide SEQ ID NO: 1, 3, or 5 that encodes it, as each sequence presents a structurally and functionally *distinct* invention not a species.**

**Additionally, Applicants must elect a single type of molecule contacted to the cancer cell or administered to a mammal: antibody (includes anti-TASK polypeptide antibody), oligonucleotide (includes antisense oligonucleotide), siRNA (includes TASK siRNA), oligopeptide (includes TASK binding oligopeptide), or organic molecule (includes TASK binding organic molecule), as each type of molecule presents a structurally and functionally *distinct* invention not a species. Claims 62-90, 101-102 will be examined as drawn to the elected invention.**

**Group IX:      Claims 91-94, drawn to a method of determining the presence of a polypeptide in a sample, classified in Class 435, subclass 7.1 and 6.**

**Additionally, Applicants must elect a single polypeptide sequence SEQ ID NO: 2, 4, or 6 and the corresponding nucleotide SEQ ID NO: 1, 3, or 5 that encodes it, as each sequence presents a structurally and functionally *distinct* invention not a species.**

**Additionally, Applicants must elect a single type of molecule exposed to the sample: antibody, oligonucleotide, siRNA, oligopeptide, or organic molecule, as each type of molecule presents a structurally and functionally *distinct***

**invention not a species.**

Group X: Claim 95, 96, 98-100, drawn to a method of diagnosing the presence of a tumor in a mammal comprising detecting the level of **expression of a gene** encoding a polypeptide, wherein the step of detecting comprises employing an **oligonucleotide** in an *in situ* hybridization or RT-PCR, and a method of diagnosing the presence of a tumor in a mammal comprising detecting the **polynucleotide** in the sample, classified in Class 435, subclass 6.

**NOTE: there is no antecedent basis for “said siRNA or oligonucleotide” in claim 98.**

**Additionally, Applicants must elect a single nucleic acid sequence SEQ ID NO: 1, 3, or 5 and the corresponding polypeptide SEQ ID NO: 2, 4, or 6 that it encodes, as each sequence presents a structurally and functionally *distinct* invention not a species.**

**Additionally, Applicants must elect a single type of molecule exposed to the sample: oligonucleotide or siRNA, as each type of molecule presents a structurally and functionally *distinct* invention not a species. CLAIMS 95, 96, 98-100 will be examined as drawn to the elected invention.**

Group XI: Claims 95, 97-100, drawn to a method of diagnosing the presence of a tumor in a mammal comprising contacting a test sample of tissue cells obtained from said mammal with an **antibody**, and said method comprising detecting the level of expression of a gene encoding a polypeptide wherein the step of detecting comprises employing an **antibody** in immunohistochemistry analysis, classified in Class 435,

subclass 7.1.

**Additionally, Applicants must elect a single polypeptide sequence SEQ ID NO: 2, 4, or 6 and the corresponding nucleotide SEQ ID NO: 1, 3, or 5 that encodes it, as each sequence presents a structurally and functionally *distinct* invention not a species.**

Group XII: Claims 98-100, drawn to a method of diagnosing the presence of a tumor in a mammal comprising detecting the **polypeptide** in a test sample of tissue cells obtained from said mammal comprising contact the test sample with an **oligopeptide or organic molecule**, classified in class 435, subclass 7.1.

**Additionally, Applicants must elect a single polypeptide sequence SEQ ID NO: 2, 4, or 6 and the corresponding nucleotide SEQ ID NO: 1, 3, or 5 that encodes it, as each sequence presents a structurally and functionally *distinct* invention not a species.**

**Additionally, Applicants must elect a single type of molecule contacted with the sample: oligopeptide or organic molecule, as each type of molecule presents a structurally and functionally *distinct* invention not a species.**

Applicants hereby elect to prosecute the invention of Group X and further electing SEQ ID NOS: 1 and 2 and further electing antibodies.

**REMARKS**

Applicants reserve their rights to file divisional applications for the non-elected claims, as well as any other matter disclosed in the present application which is not encompassed by the